This site is intended for healthcare professionals
Drug news

Phase III trial of triple therapy is initiated for VX 445, tezacaftor and ivacaftor to treat F508del mutation cystic fibrosis.- Vertex Pharma.

Read time: 1 mins
Last updated:1st May 2018
Published:1st May 2018
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest